Replimune Group said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a mid-stage study.
The therapy, RP1, in combination with cemiplimab failed to significantly remove or reduce cancerous lesions in patients compared to cemiplimab alone.
Still, the company said the combination therapy showed "clinically meaningful" activity.
https://finance.yahoo.com/news/1-replimunes-skin-cancer-drug-123211237.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.